WO2018161831A1 - Gpr84受体拮抗剂及其应用 - Google Patents
Gpr84受体拮抗剂及其应用 Download PDFInfo
- Publication number
- WO2018161831A1 WO2018161831A1 PCT/CN2018/077584 CN2018077584W WO2018161831A1 WO 2018161831 A1 WO2018161831 A1 WO 2018161831A1 CN 2018077584 W CN2018077584 W CN 2018077584W WO 2018161831 A1 WO2018161831 A1 WO 2018161831A1
- Authority
- WO
- WIPO (PCT)
- Prior art keywords
- independently
- ring
- compound
- alkyl
- group
- Prior art date
Links
- 239000002464 receptor antagonist Substances 0.000 title abstract 4
- 229940044551 receptor antagonist Drugs 0.000 title abstract 4
- 102100033864 G-protein coupled receptor 84 Human genes 0.000 claims abstract description 48
- 238000002360 preparation method Methods 0.000 claims abstract description 19
- 201000010099 disease Diseases 0.000 claims abstract description 12
- 208000037265 diseases, disorders, signs and symptoms Diseases 0.000 claims abstract description 12
- 101001069589 Homo sapiens G-protein coupled receptor 84 Proteins 0.000 claims abstract description 9
- 239000003814 drug Substances 0.000 claims abstract description 8
- 206010001497 Agitation Diseases 0.000 claims abstract description 7
- 150000001875 compounds Chemical class 0.000 claims description 59
- 125000001424 substituent group Chemical group 0.000 claims description 30
- 239000005557 antagonist Substances 0.000 claims description 18
- 229910052799 carbon Inorganic materials 0.000 claims description 16
- 238000000034 method Methods 0.000 claims description 16
- 150000003839 salts Chemical class 0.000 claims description 16
- ZRALSGWEFCBTJO-UHFFFAOYSA-N Guanidine Chemical compound NC(N)=N ZRALSGWEFCBTJO-UHFFFAOYSA-N 0.000 claims description 14
- 229910052760 oxygen Inorganic materials 0.000 claims description 14
- -1 hydroxy, mercapto, amino Chemical group 0.000 claims description 13
- 229910052717 sulfur Inorganic materials 0.000 claims description 13
- HZAXFHJVJLSVMW-UHFFFAOYSA-N 2-Aminoethan-1-ol Chemical compound NCCO HZAXFHJVJLSVMW-UHFFFAOYSA-N 0.000 claims description 12
- OKTJSMMVPCPJKN-UHFFFAOYSA-N Carbon Chemical group [C] OKTJSMMVPCPJKN-UHFFFAOYSA-N 0.000 claims description 12
- ZMANZCXQSJIPKH-UHFFFAOYSA-N Triethylamine Chemical compound CCN(CC)CC ZMANZCXQSJIPKH-UHFFFAOYSA-N 0.000 claims description 12
- 229910052794 bromium Inorganic materials 0.000 claims description 12
- 229910052740 iodine Inorganic materials 0.000 claims description 12
- 239000002994 raw material Substances 0.000 claims description 12
- 229910052791 calcium Inorganic materials 0.000 claims description 11
- 229910052801 chlorine Inorganic materials 0.000 claims description 11
- 229910052731 fluorine Inorganic materials 0.000 claims description 11
- 125000002887 hydroxy group Chemical group [H]O* 0.000 claims description 10
- 125000000753 cycloalkyl group Chemical group 0.000 claims description 9
- 229910052736 halogen Inorganic materials 0.000 claims description 9
- 150000002367 halogens Chemical class 0.000 claims description 9
- 239000008194 pharmaceutical composition Substances 0.000 claims description 9
- MSWZFWKMSRAUBD-IVMDWMLBSA-N 2-amino-2-deoxy-D-glucopyranose Chemical compound N[C@H]1C(O)O[C@H](CO)[C@@H](O)[C@@H]1O MSWZFWKMSRAUBD-IVMDWMLBSA-N 0.000 claims description 8
- GLUUGHFHXGJENI-UHFFFAOYSA-N Piperazine Chemical compound C1CNCCN1 GLUUGHFHXGJENI-UHFFFAOYSA-N 0.000 claims description 8
- NQRYJNQNLNOLGT-UHFFFAOYSA-N Piperidine Chemical compound C1CCNCC1 NQRYJNQNLNOLGT-UHFFFAOYSA-N 0.000 claims description 8
- MSWZFWKMSRAUBD-UHFFFAOYSA-N beta-D-galactosamine Natural products NC1C(O)OC(CO)C(O)C1O MSWZFWKMSRAUBD-UHFFFAOYSA-N 0.000 claims description 8
- RYYVLZVUVIJVGH-UHFFFAOYSA-N caffeine Chemical compound CN1C(=O)N(C)C(=O)C2=C1N=CN2C RYYVLZVUVIJVGH-UHFFFAOYSA-N 0.000 claims description 8
- 229960002442 glucosamine Drugs 0.000 claims description 8
- KWIUHFFTVRNATP-UHFFFAOYSA-N glycine betaine Chemical compound C[N+](C)(C)CC([O-])=O KWIUHFFTVRNATP-UHFFFAOYSA-N 0.000 claims description 8
- 238000006467 substitution reaction Methods 0.000 claims description 8
- YAPQBXQYLJRXSA-UHFFFAOYSA-N theobromine Chemical compound CN1C(=O)NC(=O)C2=C1N=CN2C YAPQBXQYLJRXSA-UHFFFAOYSA-N 0.000 claims description 8
- GETQZCLCWQTVFV-UHFFFAOYSA-N trimethylamine Chemical compound CN(C)C GETQZCLCWQTVFV-UHFFFAOYSA-N 0.000 claims description 8
- 125000004178 (C1-C4) alkyl group Chemical group 0.000 claims description 7
- CHJJGSNFBQVOTG-UHFFFAOYSA-N N-methyl-guanidine Natural products CNC(N)=N CHJJGSNFBQVOTG-UHFFFAOYSA-N 0.000 claims description 7
- 125000000217 alkyl group Chemical group 0.000 claims description 7
- 125000003178 carboxy group Chemical group [H]OC(*)=O 0.000 claims description 7
- SWSQBOPZIKWTGO-UHFFFAOYSA-N dimethylaminoamidine Natural products CN(C)C(N)=N SWSQBOPZIKWTGO-UHFFFAOYSA-N 0.000 claims description 7
- 239000003937 drug carrier Substances 0.000 claims description 7
- 125000001072 heteroaryl group Chemical group 0.000 claims description 7
- 150000002500 ions Chemical class 0.000 claims description 7
- 125000005913 (C3-C6) cycloalkyl group Chemical group 0.000 claims description 6
- YNAVUWVOSKDBBP-UHFFFAOYSA-N Morpholine Chemical compound C1COCCN1 YNAVUWVOSKDBBP-UHFFFAOYSA-N 0.000 claims description 6
- 125000003118 aryl group Chemical group 0.000 claims description 6
- 239000011347 resin Substances 0.000 claims description 5
- 229920005989 resin Polymers 0.000 claims description 5
- BFSVOASYOCHEOV-UHFFFAOYSA-N 2-diethylaminoethanol Chemical compound CCN(CC)CCO BFSVOASYOCHEOV-UHFFFAOYSA-N 0.000 claims description 4
- 229940013085 2-diethylaminoethanol Drugs 0.000 claims description 4
- 239000004475 Arginine Substances 0.000 claims description 4
- PIICEJLVQHRZGT-UHFFFAOYSA-N Ethylenediamine Chemical compound NCCN PIICEJLVQHRZGT-UHFFFAOYSA-N 0.000 claims description 4
- LPHGQDQBBGAPDZ-UHFFFAOYSA-N Isocaffeine Natural products CN1C(=O)N(C)C(=O)C2=C1N(C)C=N2 LPHGQDQBBGAPDZ-UHFFFAOYSA-N 0.000 claims description 4
- ODKSFYDXXFIFQN-BYPYZUCNSA-P L-argininium(2+) Chemical compound NC(=[NH2+])NCCC[C@H]([NH3+])C(O)=O ODKSFYDXXFIFQN-BYPYZUCNSA-P 0.000 claims description 4
- HNDVDQJCIGZPNO-YFKPBYRVSA-N L-histidine Chemical compound OC(=O)[C@@H](N)CC1=CN=CN1 HNDVDQJCIGZPNO-YFKPBYRVSA-N 0.000 claims description 4
- KDXKERNSBIXSRK-YFKPBYRVSA-N L-lysine Chemical compound NCCCC[C@H](N)C(O)=O KDXKERNSBIXSRK-YFKPBYRVSA-N 0.000 claims description 4
- UEEJHVSXFDXPFK-UHFFFAOYSA-N N-dimethylaminoethanol Chemical compound CN(C)CCO UEEJHVSXFDXPFK-UHFFFAOYSA-N 0.000 claims description 4
- HTLZVHNRZJPSMI-UHFFFAOYSA-N N-ethylpiperidine Chemical compound CCN1CCCCC1 HTLZVHNRZJPSMI-UHFFFAOYSA-N 0.000 claims description 4
- ODKSFYDXXFIFQN-UHFFFAOYSA-N arginine Natural products OC(=O)C(N)CCCNC(N)=N ODKSFYDXXFIFQN-UHFFFAOYSA-N 0.000 claims description 4
- 229960003121 arginine Drugs 0.000 claims description 4
- JUHORIMYRDESRB-UHFFFAOYSA-N benzathine Chemical compound C=1C=CC=CC=1CNCCNCC1=CC=CC=C1 JUHORIMYRDESRB-UHFFFAOYSA-N 0.000 claims description 4
- 229960003237 betaine Drugs 0.000 claims description 4
- 229960001948 caffeine Drugs 0.000 claims description 4
- VJEONQKOZGKCAK-UHFFFAOYSA-N caffeine Natural products CN1C(=O)N(C)C(=O)C2=C1C=CN2C VJEONQKOZGKCAK-UHFFFAOYSA-N 0.000 claims description 4
- OEYIOHPDSNJKLS-UHFFFAOYSA-N choline Chemical compound C[N+](C)(C)CCO OEYIOHPDSNJKLS-UHFFFAOYSA-N 0.000 claims description 4
- 229960001231 choline Drugs 0.000 claims description 4
- HPNMFZURTQLUMO-UHFFFAOYSA-N diethylamine Chemical compound CCNCC HPNMFZURTQLUMO-UHFFFAOYSA-N 0.000 claims description 4
- 229960004198 guanidine Drugs 0.000 claims description 4
- HNDVDQJCIGZPNO-UHFFFAOYSA-N histidine Natural products OC(=O)C(N)CC1=CN=CN1 HNDVDQJCIGZPNO-UHFFFAOYSA-N 0.000 claims description 4
- 229960002885 histidine Drugs 0.000 claims description 4
- JJWLVOIRVHMVIS-UHFFFAOYSA-N isopropylamine Chemical compound CC(C)N JJWLVOIRVHMVIS-UHFFFAOYSA-N 0.000 claims description 4
- 229920000768 polyamine Polymers 0.000 claims description 4
- MFDFERRIHVXMIY-UHFFFAOYSA-N procaine Chemical compound CCN(CC)CCOC(=O)C1=CC=C(N)C=C1 MFDFERRIHVXMIY-UHFFFAOYSA-N 0.000 claims description 4
- 229960004919 procaine Drugs 0.000 claims description 4
- 229910052708 sodium Inorganic materials 0.000 claims description 4
- 229960004559 theobromine Drugs 0.000 claims description 4
- 229940086542 triethylamine Drugs 0.000 claims description 4
- YFTHZRPMJXBUME-UHFFFAOYSA-N tripropylamine Chemical compound CCCN(CCC)CCC YFTHZRPMJXBUME-UHFFFAOYSA-N 0.000 claims description 4
- LENZDBCJOHFCAS-UHFFFAOYSA-N tris Chemical compound OCC(N)(CO)CO LENZDBCJOHFCAS-UHFFFAOYSA-N 0.000 claims description 4
- 229960000281 trometamol Drugs 0.000 claims description 4
- AVXURJPOCDRRFD-UHFFFAOYSA-N Hydroxylamine Chemical compound ON AVXURJPOCDRRFD-UHFFFAOYSA-N 0.000 claims description 3
- KDXKERNSBIXSRK-UHFFFAOYSA-N Lysine Natural products NCCCCC(N)C(O)=O KDXKERNSBIXSRK-UHFFFAOYSA-N 0.000 claims description 3
- 239000004472 Lysine Substances 0.000 claims description 3
- MBBZMMPHUWSWHV-BDVNFPICSA-N N-methylglucamine Chemical compound CNC[C@H](O)[C@@H](O)[C@H](O)[C@H](O)CO MBBZMMPHUWSWHV-BDVNFPICSA-N 0.000 claims description 3
- 239000002253 acid Substances 0.000 claims description 3
- 229910052782 aluminium Inorganic materials 0.000 claims description 3
- 229910052802 copper Inorganic materials 0.000 claims description 3
- 229910052742 iron Inorganic materials 0.000 claims description 3
- 229910052744 lithium Inorganic materials 0.000 claims description 3
- 229910052749 magnesium Inorganic materials 0.000 claims description 3
- 229910052748 manganese Inorganic materials 0.000 claims description 3
- 229910052751 metal Inorganic materials 0.000 claims description 3
- 239000002184 metal Substances 0.000 claims description 3
- 125000001997 phenyl group Chemical group [H]C1=C([H])C([H])=C(*)C([H])=C1[H] 0.000 claims description 3
- 229910052700 potassium Inorganic materials 0.000 claims description 3
- 229910052725 zinc Inorganic materials 0.000 claims description 3
- 125000000041 C6-C10 aryl group Chemical group 0.000 claims description 2
- 150000004032 porphyrins Chemical class 0.000 claims description 2
- 125000002924 primary amino group Chemical group [H]N([H])* 0.000 claims description 2
- OAKJQQAXSVQMHS-UHFFFAOYSA-N Hydrazine Chemical compound NN OAKJQQAXSVQMHS-UHFFFAOYSA-N 0.000 claims 2
- 239000001301 oxygen Substances 0.000 claims 1
- 208000022559 Inflammatory bowel disease Diseases 0.000 abstract description 10
- 239000000556 agonist Substances 0.000 abstract description 10
- 201000006417 multiple sclerosis Diseases 0.000 abstract description 8
- 102000005962 receptors Human genes 0.000 abstract description 8
- 108020003175 receptors Proteins 0.000 abstract description 8
- 206010003246 arthritis Diseases 0.000 abstract description 7
- 230000004913 activation Effects 0.000 abstract description 4
- 101710107771 G-protein coupled receptor 84 Proteins 0.000 description 40
- OKKJLVBELUTLKV-UHFFFAOYSA-N Methanol Chemical compound OC OKKJLVBELUTLKV-UHFFFAOYSA-N 0.000 description 33
- XEKOWRVHYACXOJ-UHFFFAOYSA-N Ethyl acetate Chemical compound CCOC(C)=O XEKOWRVHYACXOJ-UHFFFAOYSA-N 0.000 description 23
- 238000006243 chemical reaction Methods 0.000 description 23
- YMWUJEATGCHHMB-UHFFFAOYSA-N Dichloromethane Chemical compound ClCCl YMWUJEATGCHHMB-UHFFFAOYSA-N 0.000 description 19
- 239000000047 product Substances 0.000 description 16
- 239000000243 solution Substances 0.000 description 16
- IAZDPXIOMUYVGZ-UHFFFAOYSA-N DMSO Substances CS(C)=O IAZDPXIOMUYVGZ-UHFFFAOYSA-N 0.000 description 15
- 239000011575 calcium Substances 0.000 description 14
- 239000000203 mixture Substances 0.000 description 13
- 235000019439 ethyl acetate Nutrition 0.000 description 11
- 239000007787 solid Substances 0.000 description 11
- XLYOFNOQVPJJNP-UHFFFAOYSA-N water Substances O XLYOFNOQVPJJNP-UHFFFAOYSA-N 0.000 description 11
- JUJWROOIHBZHMG-UHFFFAOYSA-N Pyridine Chemical compound C1=CC=NC=C1 JUJWROOIHBZHMG-UHFFFAOYSA-N 0.000 description 10
- HEMHJVSKTPXQMS-UHFFFAOYSA-M Sodium hydroxide Chemical compound [OH-].[Na+] HEMHJVSKTPXQMS-UHFFFAOYSA-M 0.000 description 9
- YXFVVABEGXRONW-UHFFFAOYSA-N Toluene Chemical compound CC1=CC=CC=C1 YXFVVABEGXRONW-UHFFFAOYSA-N 0.000 description 9
- 239000011734 sodium Substances 0.000 description 9
- OYPRJOBELJOOCE-UHFFFAOYSA-N Calcium Chemical compound [Ca] OYPRJOBELJOOCE-UHFFFAOYSA-N 0.000 description 8
- 239000010410 layer Substances 0.000 description 8
- 239000000463 material Substances 0.000 description 8
- HPALAKNZSZLMCH-UHFFFAOYSA-M sodium;chloride;hydrate Chemical class O.[Na+].[Cl-] HPALAKNZSZLMCH-UHFFFAOYSA-M 0.000 description 8
- 210000004027 cell Anatomy 0.000 description 7
- VEXZGXHMUGYJMC-UHFFFAOYSA-N Hydrochloric acid Chemical compound Cl VEXZGXHMUGYJMC-UHFFFAOYSA-N 0.000 description 6
- 238000004440 column chromatography Methods 0.000 description 6
- 239000000975 dye Substances 0.000 description 6
- 238000010898 silica gel chromatography Methods 0.000 description 6
- 239000007858 starting material Substances 0.000 description 6
- IRBAWVGZNJIROV-SFHVURJKSA-N 9-(2-cyclopropylethynyl)-2-[[(2s)-1,4-dioxan-2-yl]methoxy]-6,7-dihydropyrimido[6,1-a]isoquinolin-4-one Chemical compound C1=C2C3=CC=C(C#CC4CC4)C=C3CCN2C(=O)N=C1OC[C@@H]1COCCO1 IRBAWVGZNJIROV-SFHVURJKSA-N 0.000 description 5
- 229940125821 GLPG1205 Drugs 0.000 description 5
- 230000003042 antagnostic effect Effects 0.000 description 5
- 239000012267 brine Substances 0.000 description 5
- FFUAGWLWBBFQJT-UHFFFAOYSA-N hexamethyldisilazane Chemical compound C[Si](C)(C)N[Si](C)(C)C FFUAGWLWBBFQJT-UHFFFAOYSA-N 0.000 description 5
- 239000002904 solvent Substances 0.000 description 5
- 239000011550 stock solution Substances 0.000 description 5
- 125000004765 (C1-C4) haloalkyl group Chemical group 0.000 description 4
- OUVXYXNWSVIOSJ-UHFFFAOYSA-N Fluo-4 Chemical compound CC1=CC=C(N(CC(O)=O)CC(O)=O)C(OCCOC=2C(=CC=C(C=2)C2=C3C=C(F)C(=O)C=C3OC3=CC(O)=C(F)C=C32)N(CC(O)=O)CC(O)=O)=C1 OUVXYXNWSVIOSJ-UHFFFAOYSA-N 0.000 description 4
- 206010061218 Inflammation Diseases 0.000 description 4
- FAPWRFPIFSIZLT-UHFFFAOYSA-M Sodium chloride Chemical compound [Na+].[Cl-] FAPWRFPIFSIZLT-UHFFFAOYSA-M 0.000 description 4
- 125000004432 carbon atom Chemical group C* 0.000 description 4
- 239000003153 chemical reaction reagent Substances 0.000 description 4
- 229940079593 drug Drugs 0.000 description 4
- 230000000694 effects Effects 0.000 description 4
- 238000009472 formulation Methods 0.000 description 4
- 230000004054 inflammatory process Effects 0.000 description 4
- 239000012074 organic phase Substances 0.000 description 4
- QUANRIQJNFHVEU-UHFFFAOYSA-N oxirane;propane-1,2,3-triol Chemical compound C1CO1.OCC(O)CO QUANRIQJNFHVEU-UHFFFAOYSA-N 0.000 description 4
- 230000008569 process Effects 0.000 description 4
- UMJSCPRVCHMLSP-UHFFFAOYSA-N pyridine Natural products COC1=CC=CN=C1 UMJSCPRVCHMLSP-UHFFFAOYSA-N 0.000 description 4
- 229920006395 saturated elastomer Polymers 0.000 description 4
- HVCNXQOWACZAFN-UHFFFAOYSA-N 4-ethylmorpholine Chemical compound CCN1CCOCC1 HVCNXQOWACZAFN-UHFFFAOYSA-N 0.000 description 3
- CSCPPACGZOOCGX-UHFFFAOYSA-N Acetone Chemical compound CC(C)=O CSCPPACGZOOCGX-UHFFFAOYSA-N 0.000 description 3
- RTZKZFJDLAIYFH-UHFFFAOYSA-N Diethyl ether Chemical compound CCOCC RTZKZFJDLAIYFH-UHFFFAOYSA-N 0.000 description 3
- WQZGKKKJIJFFOK-GASJEMHNSA-N Glucose Natural products OC[C@H]1OC(O)[C@H](O)[C@@H](O)[C@@H]1O WQZGKKKJIJFFOK-GASJEMHNSA-N 0.000 description 3
- DNIAPMSPPWPWGF-UHFFFAOYSA-N Propylene glycol Chemical compound CC(O)CO DNIAPMSPPWPWGF-UHFFFAOYSA-N 0.000 description 3
- VYPSYNLAJGMNEJ-UHFFFAOYSA-N Silicium dioxide Chemical compound O=[Si]=O VYPSYNLAJGMNEJ-UHFFFAOYSA-N 0.000 description 3
- PMZURENOXWZQFD-UHFFFAOYSA-L Sodium Sulfate Chemical compound [Na+].[Na+].[O-]S([O-])(=O)=O PMZURENOXWZQFD-UHFFFAOYSA-L 0.000 description 3
- 125000002947 alkylene group Chemical group 0.000 description 3
- 230000015572 biosynthetic process Effects 0.000 description 3
- OJCSPXHYDFONPU-UHFFFAOYSA-N etoac etoac Chemical compound CCOC(C)=O.CCOC(C)=O OJCSPXHYDFONPU-UHFFFAOYSA-N 0.000 description 3
- 239000007850 fluorescent dye Substances 0.000 description 3
- 125000000592 heterocycloalkyl group Chemical group 0.000 description 3
- 238000011534 incubation Methods 0.000 description 3
- 230000002401 inhibitory effect Effects 0.000 description 3
- 230000003834 intracellular effect Effects 0.000 description 3
- 210000002540 macrophage Anatomy 0.000 description 3
- RLOWWWKZYUNIDI-UHFFFAOYSA-N phosphinic chloride Chemical compound ClP=O RLOWWWKZYUNIDI-UHFFFAOYSA-N 0.000 description 3
- 239000000741 silica gel Substances 0.000 description 3
- 229910002027 silica gel Inorganic materials 0.000 description 3
- 0 CC*C1=CSC(CC2CCC(*)(C3)C4CC=*)[C@]5I[C@]2[C@]4IC35C(*)CC(CC2)[C@@]3I(C)*(C)CCC(C)C2(*)CCC13 Chemical compound CC*C1=CSC(CC2CCC(*)(C3)C4CC=*)[C@]5I[C@]2[C@]4IC35C(*)CC(CC2)[C@@]3I(C)*(C)CCC(C)C2(*)CCC13 0.000 description 2
- 208000014997 Crohn colitis Diseases 0.000 description 2
- 208000011231 Crohn disease Diseases 0.000 description 2
- YLQBMQCUIZJEEH-UHFFFAOYSA-N Furan Chemical group C=1C=COC=1 YLQBMQCUIZJEEH-UHFFFAOYSA-N 0.000 description 2
- PEDCQBHIVMGVHV-UHFFFAOYSA-N Glycerine Chemical compound OCC(O)CO PEDCQBHIVMGVHV-UHFFFAOYSA-N 0.000 description 2
- 239000012981 Hank's balanced salt solution Substances 0.000 description 2
- 229920002685 Polyoxyl 35CastorOil Polymers 0.000 description 2
- QOMNQGZXFYNBNG-UHFFFAOYSA-N acetyloxymethyl 2-[2-[2-[5-[3-(acetyloxymethoxy)-2,7-difluoro-6-oxoxanthen-9-yl]-2-[bis[2-(acetyloxymethoxy)-2-oxoethyl]amino]phenoxy]ethoxy]-n-[2-(acetyloxymethoxy)-2-oxoethyl]-4-methylanilino]acetate Chemical compound CC(=O)OCOC(=O)CN(CC(=O)OCOC(C)=O)C1=CC=C(C)C=C1OCCOC1=CC(C2=C3C=C(F)C(=O)C=C3OC3=CC(OCOC(C)=O)=C(F)C=C32)=CC=C1N(CC(=O)OCOC(C)=O)CC(=O)OCOC(C)=O QOMNQGZXFYNBNG-UHFFFAOYSA-N 0.000 description 2
- 239000004480 active ingredient Substances 0.000 description 2
- 210000001789 adipocyte Anatomy 0.000 description 2
- 125000003545 alkoxy group Chemical group 0.000 description 2
- 150000001412 amines Chemical class 0.000 description 2
- 150000003863 ammonium salts Chemical class 0.000 description 2
- 239000007864 aqueous solution Substances 0.000 description 2
- 159000000007 calcium salts Chemical class 0.000 description 2
- OSGAYBCDTDRGGQ-UHFFFAOYSA-L calcium sulfate Chemical compound [Ca+2].[O-]S([O-])(=O)=O OSGAYBCDTDRGGQ-UHFFFAOYSA-L 0.000 description 2
- 230000008859 change Effects 0.000 description 2
- 239000012141 concentrate Substances 0.000 description 2
- 235000008504 concentrate Nutrition 0.000 description 2
- 239000010949 copper Substances 0.000 description 2
- 239000012043 crude product Substances 0.000 description 2
- 125000000113 cyclohexyl group Chemical group [H]C1([H])C([H])([H])C([H])([H])C([H])(*)C([H])([H])C1([H])[H] 0.000 description 2
- 238000001514 detection method Methods 0.000 description 2
- 238000011161 development Methods 0.000 description 2
- 238000001035 drying Methods 0.000 description 2
- 239000002158 endotoxin Substances 0.000 description 2
- 238000002474 experimental method Methods 0.000 description 2
- 238000001914 filtration Methods 0.000 description 2
- 125000005842 heteroatom Chemical group 0.000 description 2
- 150000002430 hydrocarbons Chemical group 0.000 description 2
- 230000007062 hydrolysis Effects 0.000 description 2
- 238000006460 hydrolysis reaction Methods 0.000 description 2
- YOZNUFWCRFCGIH-BYFNXCQMSA-L hydroxocobalamin Chemical compound O[Co+]N([C@]1([H])[C@H](CC(N)=O)[C@]\2(CCC(=O)NC[C@H](C)OP(O)(=O)OC3[C@H]([C@H](O[C@@H]3CO)N3C4=CC(C)=C(C)C=C4N=C3)O)C)C/2=C(C)\C([C@H](C/2(C)C)CCC(N)=O)=N\C\2=C\C([C@H]([C@@]/2(CC(N)=O)C)CCC(N)=O)=N\C\2=C(C)/C2=N[C@]1(C)[C@@](C)(CC(N)=O)[C@@H]2CCC(N)=O YOZNUFWCRFCGIH-BYFNXCQMSA-L 0.000 description 2
- 208000027866 inflammatory disease Diseases 0.000 description 2
- 238000002347 injection Methods 0.000 description 2
- 239000007924 injection Substances 0.000 description 2
- 150000007529 inorganic bases Chemical class 0.000 description 2
- XEEYBQQBJWHFJM-UHFFFAOYSA-N iron Substances [Fe] XEEYBQQBJWHFJM-UHFFFAOYSA-N 0.000 description 2
- 239000003446 ligand Substances 0.000 description 2
- 229920006008 lipopolysaccharide Polymers 0.000 description 2
- 239000007788 liquid Substances 0.000 description 2
- 239000011777 magnesium Substances 0.000 description 2
- 159000000003 magnesium salts Chemical class 0.000 description 2
- HQKMJHAJHXVSDF-UHFFFAOYSA-L magnesium stearate Chemical compound [Mg+2].CCCCCCCCCCCCCCCCCC([O-])=O.CCCCCCCCCCCCCCCCCC([O-])=O HQKMJHAJHXVSDF-UHFFFAOYSA-L 0.000 description 2
- 150000002696 manganese Chemical class 0.000 description 2
- 239000011572 manganese Substances 0.000 description 2
- 150000004667 medium chain fatty acids Chemical class 0.000 description 2
- 239000012071 phase Substances 0.000 description 2
- 239000008389 polyethoxylated castor oil Substances 0.000 description 2
- 159000000001 potassium salts Chemical class 0.000 description 2
- 239000000843 powder Substances 0.000 description 2
- 102000004169 proteins and genes Human genes 0.000 description 2
- 108090000623 proteins and genes Proteins 0.000 description 2
- 230000035484 reaction time Effects 0.000 description 2
- 238000010992 reflux Methods 0.000 description 2
- 239000011780 sodium chloride Substances 0.000 description 2
- 159000000000 sodium salts Chemical class 0.000 description 2
- 238000003756 stirring Methods 0.000 description 2
- 238000003786 synthesis reaction Methods 0.000 description 2
- 238000012360 testing method Methods 0.000 description 2
- VZGDMQKNWNREIO-UHFFFAOYSA-N tetrachloromethane Chemical compound ClC(Cl)(Cl)Cl VZGDMQKNWNREIO-UHFFFAOYSA-N 0.000 description 2
- 238000004809 thin layer chromatography Methods 0.000 description 2
- 239000011701 zinc Substances 0.000 description 2
- FEOHYDSNGHIXOM-WLDMJGECSA-N (3R,4R,5S,6R)-3-amino-6-(hydroxymethyl)-2-methyloxane-2,4,5-triol Chemical compound CC1(O)[C@H](N)[C@@H](O)[C@H](O)[C@H](O1)CO FEOHYDSNGHIXOM-WLDMJGECSA-N 0.000 description 1
- 125000000027 (C1-C10) alkoxy group Chemical group 0.000 description 1
- WCFAPJDPAPDDAQ-UHFFFAOYSA-N 1,2-dihydropyrimidine Chemical compound C1NC=CC=N1 WCFAPJDPAPDDAQ-UHFFFAOYSA-N 0.000 description 1
- OZAIFHULBGXAKX-UHFFFAOYSA-N 2-(2-cyanopropan-2-yldiazenyl)-2-methylpropanenitrile Chemical compound N#CC(C)(C)N=NC(C)(C)C#N OZAIFHULBGXAKX-UHFFFAOYSA-N 0.000 description 1
- PFSWASUQURIOOR-UHFFFAOYSA-N 6-(octylamino)-1h-pyrimidine-2,4-dione Chemical compound CCCCCCCCNC1=CC(=O)NC(=O)N1 PFSWASUQURIOOR-UHFFFAOYSA-N 0.000 description 1
- OZAIFHULBGXAKX-VAWYXSNFSA-N AIBN Substances N#CC(C)(C)\N=N\C(C)(C)C#N OZAIFHULBGXAKX-VAWYXSNFSA-N 0.000 description 1
- NLXLAEXVIDQMFP-UHFFFAOYSA-N Ammonia chloride Chemical class [NH4+].[Cl-] NLXLAEXVIDQMFP-UHFFFAOYSA-N 0.000 description 1
- 125000006374 C2-C10 alkenyl group Chemical group 0.000 description 1
- 125000005865 C2-C10alkynyl group Chemical group 0.000 description 1
- DPACWAGVMWGOIM-UHFFFAOYSA-N CC[O](C)(C)(N=O)=C(C)C Chemical compound CC[O](C)(C)(N=O)=C(C)C DPACWAGVMWGOIM-UHFFFAOYSA-N 0.000 description 1
- BHPQYMZQTOCNFJ-UHFFFAOYSA-N Calcium cation Chemical compound [Ca+2] BHPQYMZQTOCNFJ-UHFFFAOYSA-N 0.000 description 1
- CURLTUGMZLYLDI-UHFFFAOYSA-N Carbon dioxide Chemical compound O=C=O CURLTUGMZLYLDI-UHFFFAOYSA-N 0.000 description 1
- PMATZTZNYRCHOR-CGLBZJNRSA-N Cyclosporin A Chemical compound CC[C@@H]1NC(=O)[C@H]([C@H](O)[C@H](C)C\C=C\C)N(C)C(=O)[C@H](C(C)C)N(C)C(=O)[C@H](CC(C)C)N(C)C(=O)[C@H](CC(C)C)N(C)C(=O)[C@@H](C)NC(=O)[C@H](C)NC(=O)[C@H](CC(C)C)N(C)C(=O)[C@H](C(C)C)NC(=O)[C@H](CC(C)C)N(C)C(=O)CN(C)C1=O PMATZTZNYRCHOR-CGLBZJNRSA-N 0.000 description 1
- 229930105110 Cyclosporin A Natural products 0.000 description 1
- 108010036949 Cyclosporine Proteins 0.000 description 1
- 102000004127 Cytokines Human genes 0.000 description 1
- 108090000695 Cytokines Proteins 0.000 description 1
- FBPFZTCFMRRESA-FSIIMWSLSA-N D-Glucitol Natural products OC[C@H](O)[C@H](O)[C@@H](O)[C@H](O)CO FBPFZTCFMRRESA-FSIIMWSLSA-N 0.000 description 1
- FBPFZTCFMRRESA-KVTDHHQDSA-N D-Mannitol Chemical compound OC[C@@H](O)[C@@H](O)[C@H](O)[C@H](O)CO FBPFZTCFMRRESA-KVTDHHQDSA-N 0.000 description 1
- FBPFZTCFMRRESA-JGWLITMVSA-N D-glucitol Chemical compound OC[C@H](O)[C@@H](O)[C@H](O)[C@H](O)CO FBPFZTCFMRRESA-JGWLITMVSA-N 0.000 description 1
- 229920002307 Dextran Polymers 0.000 description 1
- 208000004232 Enteritis Diseases 0.000 description 1
- VGGSQFUCUMXWEO-UHFFFAOYSA-N Ethene Chemical compound C=C VGGSQFUCUMXWEO-UHFFFAOYSA-N 0.000 description 1
- 239000001856 Ethyl cellulose Substances 0.000 description 1
- ZZSNKZQZMQGXPY-UHFFFAOYSA-N Ethyl cellulose Chemical compound CCOCC1OC(OC)C(OCC)C(OCC)C1OC1C(O)C(O)C(OC)C(CO)O1 ZZSNKZQZMQGXPY-UHFFFAOYSA-N 0.000 description 1
- 239000005977 Ethylene Substances 0.000 description 1
- CWYNVVGOOAEACU-UHFFFAOYSA-N Fe2+ Chemical class [Fe+2] CWYNVVGOOAEACU-UHFFFAOYSA-N 0.000 description 1
- 102000003688 G-Protein-Coupled Receptors Human genes 0.000 description 1
- 108090000045 G-Protein-Coupled Receptors Proteins 0.000 description 1
- 108010010803 Gelatin Proteins 0.000 description 1
- 241000282412 Homo Species 0.000 description 1
- DGAQECJNVWCQMB-PUAWFVPOSA-M Ilexoside XXIX Chemical compound C[C@@H]1CC[C@@]2(CC[C@@]3(C(=CC[C@H]4[C@]3(CC[C@@H]5[C@@]4(CC[C@@H](C5(C)C)OS(=O)(=O)[O-])C)C)[C@@H]2[C@]1(C)O)C)C(=O)O[C@H]6[C@@H]([C@H]([C@@H]([C@H](O6)CO)O)O)O.[Na+] DGAQECJNVWCQMB-PUAWFVPOSA-M 0.000 description 1
- 102000014158 Interleukin-12 Subunit p40 Human genes 0.000 description 1
- 108010011429 Interleukin-12 Subunit p40 Proteins 0.000 description 1
- 241000124008 Mammalia Species 0.000 description 1
- 229930195725 Mannitol Natural products 0.000 description 1
- 241001465754 Metazoa Species 0.000 description 1
- 208000008589 Obesity Diseases 0.000 description 1
- 235000019483 Peanut oil Nutrition 0.000 description 1
- CDBYLPFSWZWCQE-UHFFFAOYSA-L Sodium Carbonate Chemical class [Na+].[Na+].[O-]C([O-])=O CDBYLPFSWZWCQE-UHFFFAOYSA-L 0.000 description 1
- DBMJMQXJHONAFJ-UHFFFAOYSA-M Sodium laurylsulphate Chemical compound [Na+].CCCCCCCCCCCCOS([O-])(=O)=O DBMJMQXJHONAFJ-UHFFFAOYSA-M 0.000 description 1
- 235000021355 Stearic acid Nutrition 0.000 description 1
- 230000024932 T cell mediated immunity Effects 0.000 description 1
- FZWLAAWBMGSTSO-UHFFFAOYSA-N Thiazole Chemical group C1=CSC=N1 FZWLAAWBMGSTSO-UHFFFAOYSA-N 0.000 description 1
- YTPLMLYBLZKORZ-UHFFFAOYSA-N Thiophene Chemical group C=1C=CSC=1 YTPLMLYBLZKORZ-UHFFFAOYSA-N 0.000 description 1
- DPXJVFZANSGRMM-UHFFFAOYSA-N acetic acid;2,3,4,5,6-pentahydroxyhexanal;sodium Chemical compound [Na].CC(O)=O.OCC(O)C(O)C(O)C(O)C=O DPXJVFZANSGRMM-UHFFFAOYSA-N 0.000 description 1
- 210000000577 adipose tissue Anatomy 0.000 description 1
- 230000001270 agonistic effect Effects 0.000 description 1
- AZDRQVAHHNSJOQ-UHFFFAOYSA-N alumane Chemical class [AlH3] AZDRQVAHHNSJOQ-UHFFFAOYSA-N 0.000 description 1
- 125000003277 amino group Chemical group 0.000 description 1
- 239000003963 antioxidant agent Substances 0.000 description 1
- 239000012300 argon atmosphere Substances 0.000 description 1
- 125000004104 aryloxy group Chemical group 0.000 description 1
- NDGSBJSAXJUQTE-UHFFFAOYSA-N azane;phosphorous acid Chemical compound N.OP(O)O NDGSBJSAXJUQTE-UHFFFAOYSA-N 0.000 description 1
- 210000003651 basophil Anatomy 0.000 description 1
- 210000001185 bone marrow Anatomy 0.000 description 1
- 229910001424 calcium ion Inorganic materials 0.000 description 1
- 239000002775 capsule Substances 0.000 description 1
- 235000011089 carbon dioxide Nutrition 0.000 description 1
- 239000001768 carboxy methyl cellulose Substances 0.000 description 1
- 150000007942 carboxylates Chemical group 0.000 description 1
- 150000001768 cations Chemical class 0.000 description 1
- 238000004113 cell culture Methods 0.000 description 1
- 239000001913 cellulose Substances 0.000 description 1
- 229920002678 cellulose Polymers 0.000 description 1
- 229920002301 cellulose acetate Polymers 0.000 description 1
- NCEXYHBECQHGNR-UHFFFAOYSA-N chembl421 Chemical compound C1=C(O)C(C(=O)O)=CC(N=NC=2C=CC(=CC=2)S(=O)(=O)NC=2N=CC=CC=2)=C1 NCEXYHBECQHGNR-UHFFFAOYSA-N 0.000 description 1
- 208000037976 chronic inflammation Diseases 0.000 description 1
- 230000006020 chronic inflammation Effects 0.000 description 1
- 229960001265 ciclosporin Drugs 0.000 description 1
- 239000003086 colorant Substances 0.000 description 1
- 238000003271 compound fluorescence assay Methods 0.000 description 1
- 150000001879 copper Chemical class 0.000 description 1
- 239000013058 crude material Substances 0.000 description 1
- 238000002425 crystallisation Methods 0.000 description 1
- 230000008025 crystallization Effects 0.000 description 1
- 125000004093 cyano group Chemical group *C#N 0.000 description 1
- 125000000392 cycloalkenyl group Chemical group 0.000 description 1
- 125000000582 cycloheptyl group Chemical group [H]C1([H])C([H])([H])C([H])([H])C([H])([H])C([H])(*)C([H])([H])C1([H])[H] 0.000 description 1
- 125000001511 cyclopentyl group Chemical group [H]C1([H])C([H])([H])C([H])([H])C([H])(*)C1([H])[H] 0.000 description 1
- 229930182912 cyclosporin Natural products 0.000 description 1
- 230000020335 dealkylation Effects 0.000 description 1
- 238000006900 dealkylation reaction Methods 0.000 description 1
- 230000007547 defect Effects 0.000 description 1
- 206010012601 diabetes mellitus Diseases 0.000 description 1
- 239000003995 emulsifying agent Substances 0.000 description 1
- 210000003979 eosinophil Anatomy 0.000 description 1
- 235000019325 ethyl cellulose Nutrition 0.000 description 1
- 229920001249 ethyl cellulose Polymers 0.000 description 1
- 230000004129 fatty acid metabolism Effects 0.000 description 1
- 239000000945 filler Substances 0.000 description 1
- 239000000796 flavoring agent Substances 0.000 description 1
- 125000003983 fluorenyl group Chemical group C1(=CC=CC=2C3=CC=CC=C3CC12)* 0.000 description 1
- 235000013355 food flavoring agent Nutrition 0.000 description 1
- 229940083124 ganglion-blocking antiadrenergic secondary and tertiary amines Drugs 0.000 description 1
- 230000002496 gastric effect Effects 0.000 description 1
- 239000000499 gel Substances 0.000 description 1
- 239000008273 gelatin Substances 0.000 description 1
- 229920000159 gelatin Polymers 0.000 description 1
- 235000019322 gelatine Nutrition 0.000 description 1
- 235000011852 gelatine desserts Nutrition 0.000 description 1
- 235000011187 glycerol Nutrition 0.000 description 1
- 239000008187 granular material Substances 0.000 description 1
- 239000001963 growth medium Substances 0.000 description 1
- 125000005553 heteroaryloxy group Chemical group 0.000 description 1
- 125000004366 heterocycloalkenyl group Chemical group 0.000 description 1
- 102000052494 human GPR84 Human genes 0.000 description 1
- 125000004435 hydrogen atom Chemical group [H]* 0.000 description 1
- XLYOFNOQVPJJNP-UHFFFAOYSA-M hydroxide Chemical compound [OH-] XLYOFNOQVPJJNP-UHFFFAOYSA-M 0.000 description 1
- 229960001103 hydroxocobalamin Drugs 0.000 description 1
- 235000004867 hydroxocobalamin Nutrition 0.000 description 1
- 239000011704 hydroxocobalamin Substances 0.000 description 1
- 230000003832 immune regulation Effects 0.000 description 1
- 210000000987 immune system Anatomy 0.000 description 1
- 230000002757 inflammatory effect Effects 0.000 description 1
- 239000004615 ingredient Substances 0.000 description 1
- 230000005764 inhibitory process Effects 0.000 description 1
- 159000000014 iron salts Chemical class 0.000 description 1
- VDBNYAPERZTOOF-UHFFFAOYSA-N isoquinolin-1(2H)-one Chemical compound C1=CC=C2C(=O)NC=CC2=C1 VDBNYAPERZTOOF-UHFFFAOYSA-N 0.000 description 1
- 210000000265 leukocyte Anatomy 0.000 description 1
- 229910003002 lithium salt Inorganic materials 0.000 description 1
- 159000000002 lithium salts Chemical class 0.000 description 1
- 239000000314 lubricant Substances 0.000 description 1
- 235000019359 magnesium stearate Nutrition 0.000 description 1
- NXPHGHWWQRMDIA-UHFFFAOYSA-M magnesium;carbanide;bromide Chemical compound [CH3-].[Mg+2].[Br-] NXPHGHWWQRMDIA-UHFFFAOYSA-M 0.000 description 1
- 239000000594 mannitol Substances 0.000 description 1
- 235000010355 mannitol Nutrition 0.000 description 1
- 208000030159 metabolic disease Diseases 0.000 description 1
- 150000002739 metals Chemical class 0.000 description 1
- 125000000325 methylidene group Chemical group [H]C([H])=* 0.000 description 1
- 239000011259 mixed solution Substances 0.000 description 1
- 230000004048 modification Effects 0.000 description 1
- 238000012986 modification Methods 0.000 description 1
- 238000010369 molecular cloning Methods 0.000 description 1
- 210000001616 monocyte Anatomy 0.000 description 1
- 238000010172 mouse model Methods 0.000 description 1
- 210000000440 neutrophil Anatomy 0.000 description 1
- 231100000252 nontoxic Toxicity 0.000 description 1
- 230000003000 nontoxic effect Effects 0.000 description 1
- 235000020824 obesity Nutrition 0.000 description 1
- QIQXTHQIDYTFRH-UHFFFAOYSA-N octadecanoic acid Chemical compound CCCCCCCCCCCCCCCCCC(O)=O QIQXTHQIDYTFRH-UHFFFAOYSA-N 0.000 description 1
- OQCDKBAXFALNLD-UHFFFAOYSA-N octadecanoic acid Natural products CCCCCCCC(C)CCCCCCCCC(O)=O OQCDKBAXFALNLD-UHFFFAOYSA-N 0.000 description 1
- 239000004006 olive oil Substances 0.000 description 1
- 235000008390 olive oil Nutrition 0.000 description 1
- 239000012044 organic layer Substances 0.000 description 1
- COWNFYYYZFRNOY-UHFFFAOYSA-N oxazolidinedione Chemical compound O=C1COC(=O)N1 COWNFYYYZFRNOY-UHFFFAOYSA-N 0.000 description 1
- 125000002971 oxazolyl group Chemical group 0.000 description 1
- 230000003647 oxidation Effects 0.000 description 1
- 238000007254 oxidation reaction Methods 0.000 description 1
- 230000001575 pathological effect Effects 0.000 description 1
- 239000000312 peanut oil Substances 0.000 description 1
- 210000005259 peripheral blood Anatomy 0.000 description 1
- 239000011886 peripheral blood Substances 0.000 description 1
- 238000009520 phase I clinical trial Methods 0.000 description 1
- 239000000902 placebo Substances 0.000 description 1
- 229940068196 placebo Drugs 0.000 description 1
- 239000013612 plasmid Substances 0.000 description 1
- 229920005862 polyol Polymers 0.000 description 1
- 150000003077 polyols Chemical class 0.000 description 1
- 229920001296 polysiloxane Polymers 0.000 description 1
- CHKVPAROMQMJNQ-UHFFFAOYSA-M potassium bisulfate Chemical compound [K+].OS([O-])(=O)=O CHKVPAROMQMJNQ-UHFFFAOYSA-M 0.000 description 1
- 229910000343 potassium bisulfate Inorganic materials 0.000 description 1
- 239000003755 preservative agent Substances 0.000 description 1
- 150000003141 primary amines Chemical class 0.000 description 1
- 235000013772 propylene glycol Nutrition 0.000 description 1
- 125000003226 pyrazolyl group Chemical group 0.000 description 1
- 125000000714 pyrimidinyl group Chemical group 0.000 description 1
- 125000000168 pyrrolyl group Chemical group 0.000 description 1
- 238000010791 quenching Methods 0.000 description 1
- 230000001105 regulatory effect Effects 0.000 description 1
- 238000011160 research Methods 0.000 description 1
- 238000012827 research and development Methods 0.000 description 1
- 229930195734 saturated hydrocarbon Natural products 0.000 description 1
- 230000003248 secreting effect Effects 0.000 description 1
- 239000008159 sesame oil Substances 0.000 description 1
- 235000011803 sesame oil Nutrition 0.000 description 1
- 230000019491 signal transduction Effects 0.000 description 1
- 235000019812 sodium carboxymethyl cellulose Nutrition 0.000 description 1
- 229920001027 sodium carboxymethylcellulose Polymers 0.000 description 1
- 235000019333 sodium laurylsulphate Nutrition 0.000 description 1
- 229910052938 sodium sulfate Inorganic materials 0.000 description 1
- 235000011152 sodium sulphate Nutrition 0.000 description 1
- SNOOUWRIMMFWNE-UHFFFAOYSA-M sodium;6-[(3,4,5-trimethoxybenzoyl)amino]hexanoate Chemical compound [Na+].COC1=CC(C(=O)NCCCCCC([O-])=O)=CC(OC)=C1OC SNOOUWRIMMFWNE-UHFFFAOYSA-M 0.000 description 1
- 239000000600 sorbitol Substances 0.000 description 1
- 235000010356 sorbitol Nutrition 0.000 description 1
- 239000003549 soybean oil Substances 0.000 description 1
- 235000012424 soybean oil Nutrition 0.000 description 1
- 239000003381 stabilizer Substances 0.000 description 1
- 239000008117 stearic acid Substances 0.000 description 1
- 230000001954 sterilising effect Effects 0.000 description 1
- 239000000126 substance Substances 0.000 description 1
- 238000003883 substance clean up Methods 0.000 description 1
- PXQLVRUNWNTZOS-UHFFFAOYSA-N sulfanyl Chemical class [SH] PXQLVRUNWNTZOS-UHFFFAOYSA-N 0.000 description 1
- 208000024891 symptom Diseases 0.000 description 1
- 239000006188 syrup Substances 0.000 description 1
- 235000020357 syrup Nutrition 0.000 description 1
- 239000000454 talc Substances 0.000 description 1
- 229910052623 talc Inorganic materials 0.000 description 1
- 238000002626 targeted therapy Methods 0.000 description 1
- 230000008685 targeting Effects 0.000 description 1
- 229940126585 therapeutic drug Drugs 0.000 description 1
- 230000001225 therapeutic effect Effects 0.000 description 1
- 125000003396 thiol group Chemical group [H]S* 0.000 description 1
- 230000001988 toxicity Effects 0.000 description 1
- 231100000419 toxicity Toxicity 0.000 description 1
- 229910021642 ultra pure water Inorganic materials 0.000 description 1
- 239000012498 ultrapure water Substances 0.000 description 1
- 238000010200 validation analysis Methods 0.000 description 1
- 235000015112 vegetable and seed oil Nutrition 0.000 description 1
- 239000008158 vegetable oil Substances 0.000 description 1
- 239000003981 vehicle Substances 0.000 description 1
- 239000000080 wetting agent Substances 0.000 description 1
- 150000003751 zinc Chemical class 0.000 description 1
Classifications
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07F—ACYCLIC, CARBOCYCLIC OR HETEROCYCLIC COMPOUNDS CONTAINING ELEMENTS OTHER THAN CARBON, HYDROGEN, HALOGEN, OXYGEN, NITROGEN, SULFUR, SELENIUM OR TELLURIUM
- C07F9/00—Compounds containing elements of Groups 5 or 15 of the Periodic Table
- C07F9/02—Phosphorus compounds
- C07F9/06—Phosphorus compounds without P—C bonds
- C07F9/08—Esters of oxyacids of phosphorus
- C07F9/09—Esters of phosphoric acids
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/66—Phosphorus compounds
- A61K31/661—Phosphorus acids or esters thereof not having P—C bonds, e.g. fosfosal, dichlorvos, malathion or mevinphos
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/66—Phosphorus compounds
- A61K31/661—Phosphorus acids or esters thereof not having P—C bonds, e.g. fosfosal, dichlorvos, malathion or mevinphos
- A61K31/6615—Compounds having two or more esterified phosphorus acid groups, e.g. inositol triphosphate, phytic acid
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/66—Phosphorus compounds
- A61K31/665—Phosphorus compounds having oxygen as a ring hetero atom, e.g. fosfomycin
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/66—Phosphorus compounds
- A61K31/67—Phosphorus compounds having sulfur as a ring hetero atom
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/66—Phosphorus compounds
- A61K31/675—Phosphorus compounds having nitrogen as a ring hetero atom, e.g. pyridoxal phosphate
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P19/00—Drugs for skeletal disorders
- A61P19/02—Drugs for skeletal disorders for joint disorders, e.g. arthritis, arthrosis
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P29/00—Non-central analgesic, antipyretic or antiinflammatory agents, e.g. antirheumatic agents; Non-steroidal antiinflammatory drugs [NSAID]
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07F—ACYCLIC, CARBOCYCLIC OR HETEROCYCLIC COMPOUNDS CONTAINING ELEMENTS OTHER THAN CARBON, HYDROGEN, HALOGEN, OXYGEN, NITROGEN, SULFUR, SELENIUM OR TELLURIUM
- C07F9/00—Compounds containing elements of Groups 5 or 15 of the Periodic Table
- C07F9/02—Phosphorus compounds
- C07F9/06—Phosphorus compounds without P—C bonds
- C07F9/08—Esters of oxyacids of phosphorus
- C07F9/09—Esters of phosphoric acids
- C07F9/117—Esters of phosphoric acids with cycloaliphatic alcohols
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07F—ACYCLIC, CARBOCYCLIC OR HETEROCYCLIC COMPOUNDS CONTAINING ELEMENTS OTHER THAN CARBON, HYDROGEN, HALOGEN, OXYGEN, NITROGEN, SULFUR, SELENIUM OR TELLURIUM
- C07F9/00—Compounds containing elements of Groups 5 or 15 of the Periodic Table
- C07F9/02—Phosphorus compounds
- C07F9/06—Phosphorus compounds without P—C bonds
- C07F9/08—Esters of oxyacids of phosphorus
- C07F9/09—Esters of phosphoric acids
- C07F9/12—Esters of phosphoric acids with hydroxyaryl compounds
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07F—ACYCLIC, CARBOCYCLIC OR HETEROCYCLIC COMPOUNDS CONTAINING ELEMENTS OTHER THAN CARBON, HYDROGEN, HALOGEN, OXYGEN, NITROGEN, SULFUR, SELENIUM OR TELLURIUM
- C07F9/00—Compounds containing elements of Groups 5 or 15 of the Periodic Table
- C07F9/02—Phosphorus compounds
- C07F9/547—Heterocyclic compounds, e.g. containing phosphorus as a ring hetero atom
- C07F9/553—Heterocyclic compounds, e.g. containing phosphorus as a ring hetero atom having one nitrogen atom as the only ring hetero atom
- C07F9/5532—Seven-(or more) membered rings
- C07F9/5535—Seven-(or more) membered rings condensed with carbocyclic rings or ring systems
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07F—ACYCLIC, CARBOCYCLIC OR HETEROCYCLIC COMPOUNDS CONTAINING ELEMENTS OTHER THAN CARBON, HYDROGEN, HALOGEN, OXYGEN, NITROGEN, SULFUR, SELENIUM OR TELLURIUM
- C07F9/00—Compounds containing elements of Groups 5 or 15 of the Periodic Table
- C07F9/02—Phosphorus compounds
- C07F9/547—Heterocyclic compounds, e.g. containing phosphorus as a ring hetero atom
- C07F9/655—Heterocyclic compounds, e.g. containing phosphorus as a ring hetero atom having oxygen atoms, with or without sulfur, selenium, or tellurium atoms, as the only ring hetero atoms
- C07F9/65515—Heterocyclic compounds, e.g. containing phosphorus as a ring hetero atom having oxygen atoms, with or without sulfur, selenium, or tellurium atoms, as the only ring hetero atoms the oxygen atom being part of a five-membered ring
- C07F9/65517—Heterocyclic compounds, e.g. containing phosphorus as a ring hetero atom having oxygen atoms, with or without sulfur, selenium, or tellurium atoms, as the only ring hetero atoms the oxygen atom being part of a five-membered ring condensed with carbocyclic rings or carbocyclic ring systems
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07F—ACYCLIC, CARBOCYCLIC OR HETEROCYCLIC COMPOUNDS CONTAINING ELEMENTS OTHER THAN CARBON, HYDROGEN, HALOGEN, OXYGEN, NITROGEN, SULFUR, SELENIUM OR TELLURIUM
- C07F9/00—Compounds containing elements of Groups 5 or 15 of the Periodic Table
- C07F9/02—Phosphorus compounds
- C07F9/547—Heterocyclic compounds, e.g. containing phosphorus as a ring hetero atom
- C07F9/655—Heterocyclic compounds, e.g. containing phosphorus as a ring hetero atom having oxygen atoms, with or without sulfur, selenium, or tellurium atoms, as the only ring hetero atoms
- C07F9/65525—Heterocyclic compounds, e.g. containing phosphorus as a ring hetero atom having oxygen atoms, with or without sulfur, selenium, or tellurium atoms, as the only ring hetero atoms the oxygen atom being part of a seven-(or more) membered ring
- C07F9/65527—Heterocyclic compounds, e.g. containing phosphorus as a ring hetero atom having oxygen atoms, with or without sulfur, selenium, or tellurium atoms, as the only ring hetero atoms the oxygen atom being part of a seven-(or more) membered ring condensed with carbocyclic rings or carbocyclic ring systems
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07F—ACYCLIC, CARBOCYCLIC OR HETEROCYCLIC COMPOUNDS CONTAINING ELEMENTS OTHER THAN CARBON, HYDROGEN, HALOGEN, OXYGEN, NITROGEN, SULFUR, SELENIUM OR TELLURIUM
- C07F9/00—Compounds containing elements of Groups 5 or 15 of the Periodic Table
- C07F9/02—Phosphorus compounds
- C07F9/547—Heterocyclic compounds, e.g. containing phosphorus as a ring hetero atom
- C07F9/6553—Heterocyclic compounds, e.g. containing phosphorus as a ring hetero atom having sulfur atoms, with or without selenium or tellurium atoms, as the only ring hetero atoms
- C07F9/655381—Heterocyclic compounds, e.g. containing phosphorus as a ring hetero atom having sulfur atoms, with or without selenium or tellurium atoms, as the only ring hetero atoms the sulfur atom being part of a seven-(or more) membered ring
- C07F9/65539—Heterocyclic compounds, e.g. containing phosphorus as a ring hetero atom having sulfur atoms, with or without selenium or tellurium atoms, as the only ring hetero atoms the sulfur atom being part of a seven-(or more) membered ring condensed with carbocyclic rings or carbocyclic ring systems
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07F—ACYCLIC, CARBOCYCLIC OR HETEROCYCLIC COMPOUNDS CONTAINING ELEMENTS OTHER THAN CARBON, HYDROGEN, HALOGEN, OXYGEN, NITROGEN, SULFUR, SELENIUM OR TELLURIUM
- C07F9/00—Compounds containing elements of Groups 5 or 15 of the Periodic Table
- C07F9/02—Phosphorus compounds
- C07F9/547—Heterocyclic compounds, e.g. containing phosphorus as a ring hetero atom
- C07F9/6561—Heterocyclic compounds, e.g. containing phosphorus as a ring hetero atom containing systems of two or more relevant hetero rings condensed among themselves or condensed with a common carbocyclic ring or ring system, with or without other non-condensed hetero rings
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07F—ACYCLIC, CARBOCYCLIC OR HETEROCYCLIC COMPOUNDS CONTAINING ELEMENTS OTHER THAN CARBON, HYDROGEN, HALOGEN, OXYGEN, NITROGEN, SULFUR, SELENIUM OR TELLURIUM
- C07F9/00—Compounds containing elements of Groups 5 or 15 of the Periodic Table
- C07F9/02—Phosphorus compounds
- C07F9/547—Heterocyclic compounds, e.g. containing phosphorus as a ring hetero atom
- C07F9/6561—Heterocyclic compounds, e.g. containing phosphorus as a ring hetero atom containing systems of two or more relevant hetero rings condensed among themselves or condensed with a common carbocyclic ring or ring system, with or without other non-condensed hetero rings
- C07F9/65616—Heterocyclic compounds, e.g. containing phosphorus as a ring hetero atom containing systems of two or more relevant hetero rings condensed among themselves or condensed with a common carbocyclic ring or ring system, with or without other non-condensed hetero rings containing the ring system having three or more than three double bonds between ring members or between ring members and non-ring members, e.g. purine or analogs
Definitions
- the present invention relates to a ligand molecule of G protein-coupled receptor 84 (GPR84).
- GPR84 G protein-coupled receptor 84
- the ligand molecule of the present invention has an antagonistic activity of GPR84, can competitively inhibit the activation of the receptor by an agonist of GPR84, and can be used for the treatment of a related disease caused by high expression or excitability of GPR84.
- a related disease caused by high expression or excitability of GPR84.
- a related disease caused by high expression or excitability of GPR84.
- a related disease caused by high expression or excitability of GPR84.
- GPR84 G protein-coupled receptor 84
- C9-C14 medium-chain fatty acid receptor discovered by Wittenberger et al. in 2001 (J. Mol. Biol. 2001, 307, 799-813)
- GPR84 Mainly expressed in bone marrow, peripheral blood leukocytes (including neutrophils, eosinophils, basophils) and fat cells.
- LPS lipopolysaccharide
- GPR84 expression is up-regulated in monocytes/macrophages, and medium-chain fatty acids can up-regulate the expression of IL-12p40 subunit in macrophage cell line RAW264.7 by GPR84, and regulate Th1.
- the cellular immune response promotes inflammation and plays an important role in the development of inflammatory diseases such as multiple sclerosis (MS), inflammatory bowel disease, and arthritis.
- MS multiple sclerosis
- metabolic diseases such as obesity and diabetes is closely related to chronic inflammation.
- macrophages invade adipose tissue, inflammatory factors can be promoted by secreting cytokines, and GPR84 expression in adipocytes will increase, indicating that GPR84 is also involved.
- GPR84 can promote inflammation, it plays an important role in the development of inflammation-related diseases. Therefore, by inhibiting the activity of GPR84 by a GPR84 antagonist, it is possible to treat an inflammation-related disease such as multiple sclerosis, inflammatory bowel disease, arthritis and the like.
- GPR84 antagonists of GPR84 are only reported in two patents by the Belgian Galapagos Company (WO 2013/092791; WO 2014/095798). Both of these patents show that such antagonists all have a structural nucleus of dihydropyrimidine isoquinolinone.
- the company reported that the GPR84 antagonist GLPG1205 (unpublished in structure) was induced by dextran sulphate sodium (DSS) in a mouse model of inflammatory bowel disease (IBD). At 3mg/kg/d, it can relieve the symptoms of enteritis. The effect is similar to the clinically positive drug cyclosporin (20mg/kg/d) and sulfazalazine (25mg/kg/d).
- GLPG1205 may be a defect in the activity or drug-like nature of the compound itself, and GPR84 remains an effective target for targeted therapy of inflammatory diseases.
- GPR84 remains an effective target for targeted therapy of inflammatory diseases.
- the current research on GPR84 is still relatively preliminary, its detailed pathological function and its role in immune regulation remain to be further elucidated, but the discovery of GPR84 antagonist with high activity and high selectivity will continue to promote the receptor. Functional studies, target validation studies, and research and development of drugs targeting this receptor.
- Y is O or S
- Z is H, or an ion of the following metal: Li, Na, K, Ca, Mg, Cu, Fe, Zn, Al, Mn, or a conjugated acid of the following base: NH 3 , Arginine, betaine, caffeine, choline, N,N'-dibenzylethylenediamine, diethylamine, 2-diethylaminoethanol, 2-dimethylaminoethanol, aminoethanol, ethanolamine, Ethylenediamine, N-ethylmorpholine, N-ethylpiperidine, glucosamine, glucosamine, histidine, hydroxylamine, isopropylamine, lysine, methylglucamine, morpholine, piperazine Azine, piperidine, guanidine, polyamine resin, procaine, guanidine, theobromine, triethylamine, trimethylamine, tripropylamine, tromethamine, etc.;
- L 3 and L 6 are each independently O, S, NH or CH 2 ;
- Rings A, B, C, and D are each independently a C 6 -C 10 aromatic ring, a C 3 -C 10 cycloalkane ring, a C 3 -C 10 heterocycloalkane ring, a C 3 -C 10 heteroaryl ring;
- R 1 , R 2 , R 3 and R 4 are each independently represented by 1 to 4 substituents on the ring A, B, C and D, and each substituent is independently a non-hydroxy group, a thiol group, an amino group, an F, a Cl group.
- L 2 and L 5 are each independently none, CH, N;
- the rings A, B, C, and D are each independently a benzene ring, a C 3 -C 6 cycloalkane ring, a C 3 -C 6 heterocycloalkane ring, or a C 3 -C 6 heteroaryl ring.
- the rings A, B, C, and D are each independently a benzene ring, a thiophene ring, a furan ring, a pyridine ring, a pyrimidine ring, an oxazole ring, a thiazole ring, a pyrazole ring, a pyrrole ring, a furan ring. a cyclohexane ring, a cyclopentane ring or a cycloheptane ring.
- R 1 , R 2 , R 3 , R 4 are each independently represented by 1 or 2 or 3 substituents on Ring A, B, C, D, each independently being none, substituted or not Substituted C 1 -C 4 alkyl, -C r H 2r -L 7 -C s H 2s+1 , -C r H 2r -N(C t H 2t+1 )-C s H 2s+1 , hydroxyl , fluorenyl, amino, F, Cl, Br; the above substitution means having one or more substituents selected from the group consisting of halogen, hydroxy, amino, -COOC 1 -C 6 alkyl, -COOH, and L 7 are each independently
- the ground is O, S, and NH, and each r is independently an integer of 0-4, and each s is independently an integer of 0-4, and each t is independently an integer of 1-4.
- the C 3 -C 6 oxacycloalkyl group is -C(dioxolane)-.
- L 2 and/or L 5 is CH or N
- R 1 represents 1-2 substituents on Ring A, and each substituent is independently, —O(C 1 -C 4 )alkyl, hydroxy, F, Cl, Br, I. C 1 -C 4 alkyl, C 1 -C 4 haloalkyl, -C 2 H 4 COOH, -C 2 H 4 COOC 2 H 5 .
- R 2 represents 1-2 substituents on Ring B, and each substituent is independently No, -O(C 1 -C 4 )alkyl, hydroxy, F, Cl, Br, I C 1 -C 4 alkyl, C 1 -C 4 haloalkyl, -C 2 H 4 COOH, -C 2 H 4 COOC 2 H 5 .
- R 3 represents 1-2 substituents on Ring C, and each substituent is independently, independently -O(C 1 -C 4 )alkyl, hydroxy, F, Cl, Br, I C 1 -C 4 alkyl, C 1 -C 4 haloalkyl, -C 2 H 4 COOH, -C 2 H 4 COOC 2 H 5 .
- R 4 represents 1-2 substituents on Ring D, and each substituent is independently, independently -O(C 1 -C 4 )alkyl, hydroxy, F, Cl, Br, I C 1 -C 4 alkyl, C 1 -C 4 haloalkyl, -C 2 H 4 COOH, -C 2 H 4 COOC 2 H 5 .
- the compound is:
- each of the rings and substituents described in Formula I are each independently a corresponding group of each specific compound described in the specification.
- the compound of the formula S1, the compound of the formula S2 and the compound of the formula S3 are used as a raw material to obtain a compound having the structure of the formula I,
- R 1 , R 2 , R 3 , R 4 , L 1 , L 2 , L 3 , L 4 , L 5 , L 6 , Y, Z, ring A, B, C, D are as defined above.
- X is F, Cl, Br or I.
- a third aspect of the invention provides a process for the preparation of the compound of the first aspect, the method comprising the steps of:
- the method includes the following steps:
- R 1 , R 2 , R 3 , R 4 , L 1 , L 2 , L 3 , L 4 , L 5 , L 6 , Y, Z, ring A, B, C, D are as defined above.
- X is F, Cl, Br or I.
- a pharmaceutical composition comprising the compound of the first aspect or a pharmaceutically acceptable salt
- a pharmaceutically acceptable carrier is selected from:
- a fifth aspect of the invention provides the use of a compound of the first aspect or a pharmaceutically acceptable salt or a pharmaceutical composition according to the fourth aspect, wherein the use is:
- the disease is multiple sclerosis, inflammatory bowel disease, or arthritis.
- a method for treating a related disease caused by high expression or excitability of a GPR84 receptor is provided, and a compound of the present invention or a pharmaceutically acceptable salt is administered to a patient in need thereof.
- the inventors of the present application have extensively and intensively studied to develop a novel structure of an antagonist of GPR84, which can competitively inhibit the activation of the receptor by an agonist of GPR84, and can be used for the preparation of a therapeutic GPR84 receptor.
- a drug of a related disease caused by high expression or hyperexcitability which includes multiple sclerosis, inflammatory bowel disease, arthritis, and the like. On the basis of this, the present invention has been completed.
- C 6 - C 10 means having 6 to 10 carbon atoms
- C 3 - C 6 means having 3 to 6 carbon atoms, and so on.
- An integer of 0-4 means 0, 1, 2, 3, 4; 6-10 carbon atoms means 6, 7, 8, 9, 10 carbon atoms, and so on.
- alkyl refers to a saturated linear or branched hydrocarbon group; for example, -CH 3 or -CH(CH 3 ) 2 ; an alkylene group refers to a portion of a saturated hydrocarbon group that formally eliminates two remaining monovalent hydrogens, including but not It is limited to methylene (-CH 2 -), ethylene (-CH 2 CH 2 -), and the like.
- Alkoxy refers to -O- (alkyl), including but not limited to -OCH 3, -OCH 2 CH 3 and the like.
- Cycloalkyl refers to a saturated cyclic hydrocarbon group such as a cyclohexyl group.
- Heterocycloalkyl refers to a saturated cyclic hydrocarbon group containing at least one hetero atom (e.g., N, O or S).
- a heteroaryl ring refers to an aromatic ring containing at least one hetero atom.
- the aromatic ring, heteroaryl ring, cycloalkane ring, alkyl, alkylene, alkoxy, cycloalkyl, heterocycloalkyl, and the like described herein include both substituted and unsubstituted, possible Substituents include, but are not limited to, C 1 -C 10 alkyl, C 2 -C 10 alkenyl, C 2 -C 10 alkynyl, C 3 -C 20 cycloalkyl, C 3 -C 20 cycloalkenyl, C 1 -C 20 heterocycloalkyl, C 1 -C 20 heterocycloalkenyl, C 1 -C 10 alkoxy, aryl, aryloxy, heteroaryl, heteroaryloxy, amino, hydroxy, halogen , mercapto, cyano, nitro, carboxyl and carboxylate groups, and the like.
- the GPR84 antagonist provided by the present invention is a compound having the structure of formula I:
- the compounds of formula I according to the invention are compounds prepared in the examples.
- the invention also provides a pharmaceutically acceptable salt thereof, comprising a salt of a compound of formula I which is reacted with an inorganic or organic base compound.
- Salts derived from inorganic bases include, but are not limited to, aluminum salts, ammonium salts, calcium salts, copper salts, iron salts, ferrous salts, lithium salts, magnesium salts, manganese salts, manganese salts, potassium salts, sodium salts, Zinc salts, etc. Ammonium salts, calcium salts, magnesium salts, potassium salts and sodium salts are particularly preferred.
- salts of pharmaceutically acceptable organic non-toxic bases including, but not limited to, salts of primary, secondary and tertiary amines, substituted amines including naturally occurring substituted amines, cyclic amines and basic ions Exchange resin such as arginine, betaine, caffeine, choline, N, N'-dibenzylethylenediamine, diethylamine, 2-diethylaminoethanol, 2-dimethylaminoethanol, aminoethanol , ethanolamine, ethylenediamine, N-ethylmorpholine, N-ethylpiperidine, glucosamine, glucosamine, histidine, hydroxocobalamin, isopropylamine, lysine, methylglucamine, Porphyrin, piperazine, piperidine, guanidine, polyamine resin, procaine, guanidine, theobromine, triethylamine, trimethylamine, tripropylamine, tromethamine, and the like.
- the compound of formula I can be achieved by any of the following routes 1 through 6:
- the reaction is carried out in pyridine; the reaction temperature is from 60 ° C to 100 ° C; the reaction time is about 1 to 24 hours; after the reaction is completed, it is extracted with a solvent such as AcOEt, Et 2 O, CH 2 Cl 2 or CHCl 3 , and washed with saturated brine. After drying, the solvent was removed under reduced pressure at a low temperature, and the concentrate was subjected to column chromatography to give the desired product, and the obtained product was confirmed by NMR or the like.
- a solvent such as AcOEt, Et 2 O, CH 2 Cl 2 or CHCl 3
- the reaction requires two equivalents of the raw material S1, and the obtained product P1 has a symmetrical structure.
- the reaction is formed as a mixture of three products of P1 to P3, and each product is separated by column chromatography.
- the reaction is carried out in toluene; the base used is hexamethyldisilazane, the reaction temperature is 80 ° C to 120 ° C; the reaction time is about 1 to 24 hours; after the reaction is completed, AcOEt, Et 2 O, CH 2 Cl 2 ,
- the solvent is extracted by a solvent such as CHCl 3 and washed with a saturated aqueous sodium chloride solution. After drying, the solvent is removed under reduced pressure at a low temperature, and the concentrate is subjected to column chromatography to give the desired product.
- the reaction requires two equivalents of the raw material S1, and the obtained product P1 has a symmetrical structure.
- the reaction is formed into a mixture of three products of P1 to P3, and each product is separated by column chromatography.
- the raw material P2 is dissolved in EA, and the aqueous solution of the base (the conjugate base of M, the hydroxide of M or the carbonic acid compound of M) is added twice, the aqueous layer is back-extracted with EA, the EA layer is concentrated, and the crude product is subjected to silica gel column chromatography.
- the product P4 was obtained.
- M is a cation of the following metals: Li, Na, K, Ca, Mg, Cu, Fe, Zn, Al, Mn;
- a conjugated acid of the following base NH 3 , arginine, betaine, caffeine, choline, N, N'-dibenzylethylenediamine, diethylamine, 2-diethylaminoethanol, 2- Dimethylaminoethanol, aminoethanol, ethanolamine, ethylenediamine, N-ethylmorpholine, N-ethylpiperidine, glucosamine, glucosamine, histidine, hydroxylamine, isopropylamine, lysine Acid, methyl glucosamine, morpholine, piperazine, piperidine, guanidine, polyamine resin, procaine, guanidine, theobromine, triethylamine, trimethylamine, tripropylamine, tromethamine, etc.; other Each substituent is as defined above.
- R1' is a C1-C4 alkyl group, and the other substituents are as defined above.
- R 5 is a C1-C4 alkyl group
- L 7 is a C1-C4 alkylene group, and the other substituents are as defined above.
- the starting material P9 was dissolved in MeOH, and a solution of Oxone in H 2 O was added dropwise with stirring at room temperature, and allowed to react at room temperature overnight.
- the reaction solution was diluted with water, extracted with EA, washed with brine, concentrated with organic layer, and purified by silica gel column chromatography.
- the compound of the formula I as an antagonist of GPR84, is capable of competitively inhibiting the activation of the receptor by an agonist of GPR84, and can be used for the preparation of a medicament for treating a disease caused by high expression or excitability of the GPR84 receptor.
- the diseases include multiple sclerosis, inflammatory bowel disease, arthritis and the like.
- compositions of the present invention comprise a therapeutically effective amount of a compound of formula I or a pharmaceutically acceptable salt thereof, and one or more pharmaceutically acceptable carriers.
- “Pharmaceutically acceptable carrier”, “pharmaceutically acceptable carrier” or “pharmaceutically acceptable carrier” means one or more compatible solid or liquid fillers or gel materials which are suitable for human use and which Must have sufficient purity and low enough toxicity.
- “compatibility” it is meant herein that the components of the composition are capable of intermixing with the active ingredient of the present invention (a compound of formula I or a pharmaceutically acceptable salt thereof) and the like, without significantly reducing the active ingredient. The efficacy of the drug.
- Examples of pharmaceutically acceptable carriers are cellulose and its derivatives (such as sodium carboxymethylcellulose, sodium ethylcellulose, cellulose acetate, etc.), gelatin, talc, solid lubricants (such as stearic acid, Magnesium stearate), calcium sulfate, vegetable oil (such as soybean oil, sesame oil, peanut oil, olive oil, etc.), polyol (such as propylene glycol, glycerin, mannitol, sorbitol, etc.), emulsifier Wetting agents (such as sodium lauryl sulfate), colorants, flavoring agents, stabilizers, antioxidants, preservatives, pyrogen-free water, and the like.
- solid lubricants such as stearic acid, Magnesium stearate
- calcium sulfate such as soybean oil, sesame oil, peanut oil, olive oil, etc.
- polyol such as propylene glycol, glycerin, mannito
- the compounds and pharmaceutical compositions of the present invention may be in various forms, and may be administered orally or in the form of an injection, such as a capsule, a tablet, a granule, a solution, a powder, a powder or a syrup, or the present invention.
- the compounds and pharmaceutical compositions may be presented in a suitable solid or liquid vehicle and in a suitable sterilizing device for injection or drip.
- the above formulations can be prepared by conventional pharmaceutical methods.
- the compounds and pharmaceutical compositions of this invention are useful for clinical use in mammals, including humans and animals, and can be administered by the oral, nasal or gastrointestinal routes.
- the most preferred route of administration is oral.
- NMR was measured using a Mercury-VX 300M or Mercury-VX400M instrument manufactured by Varian, NMR calibration: ⁇ H 7.26 ppm (CDCl 3 ), 2.50 ppm (DMSO-d 6 ), 3.15 ppm (CD 3 OD).
- the reagents are mainly supplied by Shanghai Chemical Reagent Company; the TLC thin layer chromatography silica gel plate is produced by Shandong Yantai Huiyou Silicone Development Co., Ltd., model HSGF 254; the normal phase column chromatography silica gel used for compound purification is produced by Shandong Qingdao Marine Chemical Plant Branch. , model zcx-11, 200-300 mesh.
- G1 synthetic reference J. Med. Chem. 2010, 53, 7021 - 7034; PCT Int. Appl., 2009016085, 05 Feb 2009.
- Analogs of G1, some of which can be purchased from reagent companies, are prepared using the same or similar routes as for the synthesis of G1.
- the raw material G2 was purchased from a reagent company, and the synthesis of the raw material G3 was carried out in the same synthetic route as G1.
- the starting material G2 (62.7 mg, 0.192 mmol), G3 (49.2 mg, 0.192 mmol) was dissolved in dry pyridine (0.5 mL), and the re-evaporated POCl 3 (21 uL, 0.230 mmol) was added dropwise under N 2 and reacted at 130 ° C for 2 h. .
- the GPR84 antagonistic activity test of the compounds of the invention was carried out.
- the human GPR84 cell line was obtained by transfecting a plasmid encoding GPR84 and G ⁇ 16 proteins in a HEK293 cell line.
- Fluorescent dye Fluo-4AM was purchased from Invitrogen.
- Intracellular Ca 2+ ion is a very important second messenger of the G protein-coupled receptor signaling pathway. When combined with G ⁇ 16 protein-coupled GPR84 and agonist, the intracellular Ca 2+ ion concentration can be significantly increased. .
- Fluo-4 is a Ca 2+ ion-specific fluorescent probe that binds quantitatively to Ca 2+ ions and fluoresces. Therefore, the agonistic or antagonistic activity of the compound is detected in a 96-well or 384-well flat-bottomed microplate using a fluorescence assay.
- Detection of receptor inhibitory effect by GPR84 antagonist After incubation with fluorescent dye Fluo-4, GPR84 cells were incubated with different concentrations of antagonistic compounds for a period of time to occupy the binding site of agonist to GPR84 (antagonistic binding site). Add a certain concentration of agonist (6-OAU), compete with the antagonist compound for binding sites, and simultaneously use a light source with a wavelength of 485 nm to excite and detect changes in the fluorescence intensity of the dye caused by changes in intracellular calcium concentration at the 525 nm band. PRISM software calculated half-maximum inhibition concentration (IC 50).
- HBSS 0.4 g/L KCl (5.4 mM), 0.12 g/L Na 2 HPO 4 ⁇ 12H 2 O (0.3 mM), 0.06 g/L KH 2 PO 4 (0.4 mM), 0.35 g/L NaHCO 3 ( 4.2 mM), 0.14 g/L CaCl 2 (1.3 mM), 0.10 g/L MgCl 2 ⁇ 6H 2 O (0.5 mM), 0.05 g/L MgSO 4 (0.6 mM), 8.0 g/L NaCl (137 mM), The above ingredients were weighed and dissolved in ultrapure water, adjusted to pH 7.4 with hydrochloric acid or NaOH solution, filtered, and stored at 4 ° C for one month.
- Preparation of calcium buffer first prepare 560 mM D-glucose (100X) aqueous solution, 250 mM 1,2-diphenyl-4-(2-phenylsulfinyl)ethyl-3,5-pyrazolidinedione ( 1000X) stock solution. Then add BSA (0.5g), 560mM D-glucose stock solution (1mL) and 250mM 1,2-diphenyl-4-(2-phenylsulfinyl)ethyl-3,5-pyrene in 100mL HBSS.
- the cells were seeded at a density of 40,000/well on a 96-well cell culture plate, and culture was continued for 24 hours or more to make the cell density to 80 to 90% for experimental detection. Aspirate the culture medium in the well to be tested, add 40 ⁇ L/well of freshly prepared dye, and incubate in a 37-degree incubator for 40 min to 50 min.
- Formulation of the compound during cell incubation (this step can also be prepared in advance): Dilute the compound used as the antagonist to 1.5 times the final working concentration with freshly prepared calcium buffer before the experiment, and dilute the compound used as the agonist to the final work. Three times the concentration (if the DMSO dissolved compound should ensure that the DMSO concentration does not exceed 1% at the end of the work).
- the dye is discarded, washed with calcium buffer and then replaced with 50 ⁇ L of calcium buffer containing different concentrations of antagonist for another 10 min.
Landscapes
- Chemical & Material Sciences (AREA)
- Health & Medical Sciences (AREA)
- Organic Chemistry (AREA)
- Life Sciences & Earth Sciences (AREA)
- General Health & Medical Sciences (AREA)
- Biochemistry (AREA)
- Molecular Biology (AREA)
- Veterinary Medicine (AREA)
- Medicinal Chemistry (AREA)
- Pharmacology & Pharmacy (AREA)
- Animal Behavior & Ethology (AREA)
- Public Health (AREA)
- General Chemical & Material Sciences (AREA)
- Chemical Kinetics & Catalysis (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- Engineering & Computer Science (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Epidemiology (AREA)
- Rheumatology (AREA)
- Biomedical Technology (AREA)
- Neurosurgery (AREA)
- Neurology (AREA)
- Orthopedic Medicine & Surgery (AREA)
- Physical Education & Sports Medicine (AREA)
- Pain & Pain Management (AREA)
- Immunology (AREA)
- Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
Abstract
Description
Claims (10)
- 一种具有式I所示结构的化合物或药学上可接受的盐,式中,Y为O或S;Z为H,或以下金属的离子:Li、Na、K、Ca、Mg、Cu、Fe、Zn、Al、Mn,或以下碱的共轭酸:NH 3、精氨酸、甜菜碱、咖啡因、胆碱、N,N'-二苄基乙二胺、二乙胺、2-二乙基氨基乙醇、2-二甲基氨基乙醇、氨基乙醇、乙醇胺、乙二胺、N-乙基吗啉、N-乙基哌啶、葡萄糖胺、氨基葡萄糖、组氨酸、羟钴胺、异丙基胺、赖氨酸、甲基葡萄糖胺、吗啉、哌嗪、哌啶、呱咤、多胺树脂、普鲁卡因、嘌呤、可可碱、三乙胺、三甲胺、三丙胺、氨基丁三醇;L 3、L 6各自独立地为O、S、NH或CH 2;环A、B、C、D各自独立地为C 6-C 10芳环、C 3-C 10环烷烃环、C 3-C 10杂环烷烃环、C 3-C 10杂芳环;R 1、R 2、R 3、R 4各自独立地表示为环A、B、C、D上1-4个取代基,各取代基各自独立地为无、羟基、巯基、氨基、F、Cl、Br、I、-C rH 2r-L 7-C sH 2s+1、-C rH 2r-N(C tH 2t+1)-C sH 2s+1、取代或未取代的C 1~C 6烷基、取代或未取代的C 3~C 6环烷基、取代或未取代的C 6~C 10芳基、取代或未取代的C 3~C 10杂芳基,上述取代是指具有选自下组的一个或多个取代基:C 1~C 6烷基、C 1~C 6烷氧基、卤素、羟基、氨基、-COOC 1~C 6烷基、-COOH;L 7各自独立地为O、S、NH,各r独立为0-6的整数,各s独立为0-6的整数,各t独立为1-6的整数;L 2、L 5各自独立地为无、CH、N;L 1、L 4各自独立地为无、CH、O、S、SO、SO 2、-CH=CH-、CO、-C(=CH 2)-、取代或未取代的C 1~C 6亚烷基、-NH-、-N(C 1~C 4烷基)-、C 3~C 6环烷基或C 3~C 6杂环烷基,所述取代是指具有选自下组的一个或多个取代基:C 1~C 6烷基、C 1~C 6烷氧基、卤素、羟基;
- 如权利要求1所述的化合物,其特征在于,环A、B、C、D各自独立地为苯环、C 3-C 6环烷烃环、C 3-C 6杂环烷烃环、C 3-C 6杂芳环。
- 如权利要求1所述的化合物,其特征在于,R 1、R 2、R 3、R 4各自独立地表示为环A、B、C、D上1或2或3个取代基,各自独立地为无、取代或未取代的C 1~C 4烷基、-C rH 2r-L 7-C sH 2s+1、-C rH 2r-N(C tH 2t+1)-C sH 2s+1、羟基、巯基、氨基、F、Cl、Br、I;上述取代是指具有选自下组的一个或多个取代基:卤素、羟基、氨基、-COOC 1~C 6烷基、-COOH,L 7各自独立地为O、S、NH,各r独立为0-4的整数,各s独立为0-4的整数,各t独立为1-4的整数。
- 如权利要求1所述的化合物,其特征在于,L 1、L 4各自独立地为无、CH、O、S、SO、SO 2、-CH=CH-、CO、-C(=CH 2)-、取代或未取代的C 1~C 4亚烷基、-NH-、-N(C 1~C 3烷基)-、C 3~C 6环烷基或C 3~C 6氧杂环烷基,所述取代是指具有选自下组的一个或多个取代基:C 1~C 6烷基、C 1~C 6烷氧基、卤素、羟基。
- 如权利要求1所述的化合物,其特征在于,L 2和/或L 5为无时,与L 3和/或L 6相连的碳与环B和/或环D的碳形成-CH=CH-;或L 2和/或L 5为CH或N时,与L 3和/或L 6相连的碳与L 2和/或L 5形成-CH=CH-或-CH=N-。
- 一种药物组合物,其特征在于,所述药物组合物包含权利要求1-6任一项所述的化合物或药学上可接受的盐;以及药学上可接受的载体。
- 根据权利要求1所述的化合物或药学上可接受的盐,或权利要求9所述的的药物组合物的用途,其特征在于,所述用途为:(i)用于制备GPR84拮抗剂;(ii)用作GPR84拮抗剂;(iii)用于制备治疗GPR84受体高表达或兴奋性过高所导致的相关疾病的药物。
Priority Applications (4)
Application Number | Priority Date | Filing Date | Title |
---|---|---|---|
US16/490,837 US11098071B2 (en) | 2017-03-06 | 2018-02-28 | GPR84 receptor antagonist and use thereof |
JP2019548461A JP6918957B2 (ja) | 2017-03-06 | 2018-02-28 | Gpr84受容体拮抗剤およびその使用 |
EP18763472.0A EP3594221B1 (en) | 2017-03-06 | 2018-02-28 | Gpr84 receptor antagonist and use thereof |
KR1020197028924A KR102305710B1 (ko) | 2017-03-06 | 2018-02-28 | Gpr84 수용체 길항제 및 이의 용도 |
Applications Claiming Priority (2)
Application Number | Priority Date | Filing Date | Title |
---|---|---|---|
CN201710128201.3 | 2017-03-06 | ||
CN201710128201 | 2017-03-06 |
Publications (1)
Publication Number | Publication Date |
---|---|
WO2018161831A1 true WO2018161831A1 (zh) | 2018-09-13 |
Family
ID=63447204
Family Applications (1)
Application Number | Title | Priority Date | Filing Date |
---|---|---|---|
PCT/CN2018/077584 WO2018161831A1 (zh) | 2017-03-06 | 2018-02-28 | Gpr84受体拮抗剂及其应用 |
Country Status (6)
Country | Link |
---|---|
US (1) | US11098071B2 (zh) |
EP (1) | EP3594221B1 (zh) |
JP (1) | JP6918957B2 (zh) |
KR (1) | KR102305710B1 (zh) |
CN (1) | CN108530480B (zh) |
WO (1) | WO2018161831A1 (zh) |
Cited By (6)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
WO2021122415A1 (en) | 2019-12-19 | 2021-06-24 | Bayer Aktiengesellschaft | Furoindazole derivatives |
WO2022179940A1 (en) | 2021-02-23 | 2022-09-01 | Bayer Aktiengesellschaft | Furoindazole derivatives as gpr84 antagonists |
WO2022229061A1 (en) | 2021-04-29 | 2022-11-03 | Bayer Aktiengesellschaft | Furoindazole derivatives as antagonists or inhibitors of gpr84 |
WO2023284794A1 (zh) | 2021-07-15 | 2023-01-19 | 中国科学院上海药物研究所 | 不对称gpr84拮抗剂及其用途 |
US11820751B2 (en) | 2021-01-27 | 2023-11-21 | Vandria Sa | Urolithin derivatives and methods of use thereof |
WO2024083705A1 (en) | 2022-10-18 | 2024-04-25 | Bayer Aktiengesellschaft | Furoindazole derivatives for the treatment of pain |
Families Citing this family (1)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
WO2020007342A1 (zh) * | 2018-07-06 | 2020-01-09 | 中国科学院上海药物研究所 | 联苯磷酸酯类化合物作为gpr84拮抗剂的应用 |
Citations (3)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
WO2009016085A1 (en) | 2007-07-27 | 2009-02-05 | Glaxo Group Limited | Spiro compounds useful as antagonists of the h1 receptor |
WO2013092791A1 (en) | 2011-12-22 | 2013-06-27 | Galapagos Nv | Novel dihydropyrimidinoisoquinolinones and pharmaceutical compositions thereof for the treatment of inflammatory disorders |
WO2014095798A1 (en) | 2012-12-20 | 2014-06-26 | Galapagos Nv | Novel dihydropyrimidinoisoquinolinones and pharmaceutical compositions thereof for the treatment of inflammatory disorders (gpr84 antagonists) |
Family Cites Families (3)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
WO2008042867A2 (en) * | 2006-09-29 | 2008-04-10 | Emiliem Inc. | Modulators of multiple kinases |
WO2008141438A1 (en) * | 2007-05-17 | 2008-11-27 | Sunnybrook Health Sciences Centre | Gabaergic modulators for treating airway conditions |
GB201411241D0 (en) | 2014-06-25 | 2014-08-06 | Galapagos Nv | Novel dihydropyridoisoquinolinones and pharmaceutical compositions thereof for the treatment of inflammatory disorders |
-
2018
- 2018-02-28 KR KR1020197028924A patent/KR102305710B1/ko active IP Right Grant
- 2018-02-28 CN CN201810168007.2A patent/CN108530480B/zh active Active
- 2018-02-28 WO PCT/CN2018/077584 patent/WO2018161831A1/zh unknown
- 2018-02-28 JP JP2019548461A patent/JP6918957B2/ja active Active
- 2018-02-28 EP EP18763472.0A patent/EP3594221B1/en active Active
- 2018-02-28 US US16/490,837 patent/US11098071B2/en active Active
Patent Citations (5)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
WO2009016085A1 (en) | 2007-07-27 | 2009-02-05 | Glaxo Group Limited | Spiro compounds useful as antagonists of the h1 receptor |
WO2013092791A1 (en) | 2011-12-22 | 2013-06-27 | Galapagos Nv | Novel dihydropyrimidinoisoquinolinones and pharmaceutical compositions thereof for the treatment of inflammatory disorders |
CN103998448A (zh) * | 2011-12-22 | 2014-08-20 | 加拉帕戈斯股份有限公司 | 用于治疗炎性疾病的新的二氢嘧啶并异喹啉酮化合物及其药用组合物 |
WO2014095798A1 (en) | 2012-12-20 | 2014-06-26 | Galapagos Nv | Novel dihydropyrimidinoisoquinolinones and pharmaceutical compositions thereof for the treatment of inflammatory disorders (gpr84 antagonists) |
CN104870445A (zh) * | 2012-12-20 | 2015-08-26 | 加拉帕戈斯股份有限公司 | 用于治疗炎性疾病的新二氢嘧啶并异喹啉酮类及其药物组合物(gpr84拮抗剂) |
Non-Patent Citations (5)
Title |
---|
GULLAND, J. MASSON: "Constitution of yeast ribonucleic acid. XI. Synthesis of uridine 2'-phosphate", JOURNAL OF THE CHEMICAL SOCIETY, vol. 169, 1 January 1947 (1947-01-01), pages 338 - 342, XP055605931 * |
J CROHNS COLITIS, vol. 9, no. 1, 2015, pages S387 - 3 |
J. MED. CHEM., vol. 53, 2010, pages 7021 - 7034 |
SAMBROOK ET AL.: "Molecular Cloning: Laboratory Manual", 1989, COLD SPRING HARBOR LABORATORY PRESS |
WITTENBERGER ET AL., J. MOL. BIOL. 2001, vol. 307, 2001, pages 799 - 813 |
Cited By (6)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
WO2021122415A1 (en) | 2019-12-19 | 2021-06-24 | Bayer Aktiengesellschaft | Furoindazole derivatives |
US11820751B2 (en) | 2021-01-27 | 2023-11-21 | Vandria Sa | Urolithin derivatives and methods of use thereof |
WO2022179940A1 (en) | 2021-02-23 | 2022-09-01 | Bayer Aktiengesellschaft | Furoindazole derivatives as gpr84 antagonists |
WO2022229061A1 (en) | 2021-04-29 | 2022-11-03 | Bayer Aktiengesellschaft | Furoindazole derivatives as antagonists or inhibitors of gpr84 |
WO2023284794A1 (zh) | 2021-07-15 | 2023-01-19 | 中国科学院上海药物研究所 | 不对称gpr84拮抗剂及其用途 |
WO2024083705A1 (en) | 2022-10-18 | 2024-04-25 | Bayer Aktiengesellschaft | Furoindazole derivatives for the treatment of pain |
Also Published As
Publication number | Publication date |
---|---|
JP6918957B2 (ja) | 2021-08-11 |
US20200010492A1 (en) | 2020-01-09 |
JP2020510017A (ja) | 2020-04-02 |
CN108530480B (zh) | 2022-06-28 |
KR20190126835A (ko) | 2019-11-12 |
EP3594221A4 (en) | 2020-08-05 |
EP3594221A1 (en) | 2020-01-15 |
KR102305710B1 (ko) | 2021-09-30 |
CN108530480A (zh) | 2018-09-14 |
US11098071B2 (en) | 2021-08-24 |
EP3594221B1 (en) | 2021-06-30 |
Similar Documents
Publication | Publication Date | Title |
---|---|---|
WO2018161831A1 (zh) | Gpr84受体拮抗剂及其应用 | |
TWI833829B (zh) | 聯苯類化合物,其中間體,製備方法,藥物組合物及應用 | |
JP5376956B2 (ja) | デュシェンヌ型筋ジストロフィーの治療 | |
US6387938B1 (en) | Benzimidazole derivatives | |
WO2020190774A1 (en) | Novel small molecule inhibitors of tead transcription factors | |
CA2998793A1 (en) | Hepatitis b core protein modulators | |
EP0443568A1 (en) | Fused thiophene derivatives, their production and use | |
JP2008501762A (ja) | バニロイドアンタゴニストとして有用なクロモン誘導体 | |
KR20160006207A (ko) | 사이클로알킬산 유도체, 그의 제조 방법, 및 그의 약학적 용도 | |
CA3063111A1 (en) | Histone deacetylases (hdacs) inhibitors | |
WO2017152857A1 (zh) | 一种含氮烷基化和芳基化亚砜亚胺的吲哚胺-2,3-双加氧酶抑制剂 | |
JP2016500080A (ja) | ビスβ−カルボリン系化合物、その製造方法、医薬組成物および用途 | |
JPH10182583A (ja) | 新規ヒドロキサム酸誘導体 | |
JP6850361B2 (ja) | キナーゼを選択的に阻害する化合物及びその使用 | |
JP7278945B2 (ja) | 抗癌剤としてのベンゾイミダゾール誘導体 | |
JPH11269140A (ja) | 分化誘導剤 | |
WO2018157801A1 (zh) | 氰基取代的稠合双环衍生物及其制备方法和用途 | |
WO2010010935A1 (ja) | 光学活性なヘテロシクリデン-n-アリールアセトアミド誘導体 | |
WO2020007342A1 (zh) | 联苯磷酸酯类化合物作为gpr84拮抗剂的应用 | |
AU2017380492B2 (en) | Sulfonyl amidine as indoleamine-2,3-dioxygenase inhibitor, and preparation method therefor and use thereof | |
JP6867998B2 (ja) | ガンを処置するのに使用するための置換疎水性ベンゼンスルホンアミドチアゾール化合物 | |
WO2019233366A1 (zh) | 选择性a 2a受体拮抗剂 | |
KR20000022398A (ko) | 신규 벤조이미다졸 유도체 | |
JP7148769B2 (ja) | 複素環化合物又はその塩、gpr35作動薬及び医薬組成物 | |
JPH0386884A (ja) | ベンゾピラノピリジン誘導体 |
Legal Events
Date | Code | Title | Description |
---|---|---|---|
121 | Ep: the epo has been informed by wipo that ep was designated in this application |
Ref document number: 18763472 Country of ref document: EP Kind code of ref document: A1 |
|
ENP | Entry into the national phase |
Ref document number: 2019548461 Country of ref document: JP Kind code of ref document: A |
|
NENP | Non-entry into the national phase |
Ref country code: DE |
|
ENP | Entry into the national phase |
Ref document number: 20197028924 Country of ref document: KR Kind code of ref document: A |
|
ENP | Entry into the national phase |
Ref document number: 2018763472 Country of ref document: EP Effective date: 20191007 |